Preference for pharmacological management of patients with essential hypertension among senior physicians within Northern Ireland

被引：0
作者：
Murphy, J. C. [1 ]
Darragh, K. [1 ]
Hamilton, A. [1 ]
Manoharan, G. [1 ]
Adgey, A. A. J. [1 ]
机构：
[1] Royal Victoria Hosp, Reg Med Cardiol Ctr, Belfast BT12 6BA, Antrim, North Ireland
来源：
JOURNAL OF HUMAN HYPERTENSION | 2007年 / 21卷 / 12期
关键词：
D O I：
10.1038/sj.jhh.1002246
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
In Northern Ireland, as elsewhere, hypertension remains a leading cause of morbidity and mortality. Controversy has existed for many years regarding the optimal pharmacological agents for the management of this condition. However, in the UK, both historical and more recent data show that in clinical practice beta-blockers and diuretics are the most commonly prescribed first- line agents for blood pressure (BP) management.
引用
收藏
页码：969 / 972
页数：4
相关论文
共 12 条
  • [1] [Anonymous], 1991, JAMA, V265, P3255
  • [2] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [3] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial
    Dahlöf, B
    Sever, PS
    Poulter, NR
    Wedel, H
    Beevers, DG
    Caulfield, M
    Collins, R
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Östergren, J
    [J]. LANCET, 2005, 366 (9489) : 895 - 906
  • [4] Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension:: the Nordic Diltiazem (NORDIL) study
    Hansson, L
    Hedner, T
    Lund-Johansen, P
    Kjeldsen, SE
    Lindholm, LH
    Syvertsen, JO
    Lanke, J
    de Faire, U
    Dahlöf, B
    Karlberg, BE
    [J]. LANCET, 2000, 356 (9227) : 359 - 365
  • [5] Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Lindholm, LH
    Ibsen, H
    Dahlöf, B
    Devereux, RB
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Julius, S
    Kjeldsen, SE
    Kristiansson, K
    Lederballe-Pedersen, O
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    Aurup, P
    Edelman, J
    Snapinn, S
    [J]. LANCET, 2002, 359 (9311) : 1004 - 1010
  • [6] Should β blockers remain first choice in the treatment of primary hypertension?: A meta-analysis
    Lindholm, LH
    Carlberg, B
    Samuelsson, O
    [J]. LANCET, 2005, 366 (9496) : 1545 - 1553
  • [7] MEADE TW, 1992, BMJ-BRIT MED J, V304, P405
  • [8] Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
    Staessen, JA
    Fagard, R
    Thijs, L
    Celis, H
    Arabidze, GG
    Birkenhager, WH
    Bulpitt, CJ
    deLeeuw, PW
    Dollery, CT
    Fletcher, AE
    Forette, F
    Leonetti, G
    Nachev, C
    OBrien, ET
    Rosenfeld, J
    Rodicio, JL
    Tuomilehto, J
    Zanchetti, A
    [J]. LANCET, 1997, 350 (9080) : 757 - 764
  • [9] Treatment for newly diagnosed hypertension: patterns of prescribing and anti hypertensive effectiveness in the UK
    Walley, T
    Duggan, AK
    Haycox, AR
    Niziol, CJ
    [J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2003, 96 (11) : 525 - 531
  • [10] WILHELMSEN L, 1993, J HUM HYPERTENS, V7, P257
12